In this paper, we describe a protocol for hematopoietic differentiation of human pluripotent stem cells ( 
IntroDuctIon
Pluripotent stem cells are defined as cells capable of self-renewal and of giving rise to derivatives of all three germ layers (ectoderm, endoderm and mesoderm). The first expandable in vitro hPSCs, human embryonic stem cells (hESCs), were successfully derived from a blastocyst in 1998 (ref. 1) . Since then, hESCs have already become valuable models for the study of early human development and in vitro analysis of lineage commitment and differentiation. In 2006, Yamanaka and colleagues 2 revealed that mouse fibroblasts could be reprogrammed to pluripotency using four transcription factors. A year later, induced pluripotent stem cells (iPSCs) were obtained from human somatic cells 3, 4 . Because iPSCs can be generated from patients with various diseases, they can be used to obtain cells and progenitors carrying a disease-specific genetic trait and to investigate the impact of this trait on the disease's phenotypic development. In addition, iPSCs could potentially provide an unlimited supply of cells for drug testing.
Three major approaches have been developed to induce hematopoietic differentiation from hESCs. They include the embryoid body method [5] [6] [7] , coculture of hESCs with stromal cells lines [8] [9] [10] [11] and 2D culture systems 12 . The protocol described here uses the coculture of pluripotent stem cells on OP9 mouse bone marrow stromal cells to induce blood formation. The major advantage of the OP9 system is that efficient hematopoietic differentiation from hESCs can be achieved within a short period of time (8-9 d) and without added cytokines. OP9 coculture can be used to obtain multipotent hematopoietic progenitors and mature cells including T and B lymphocytes 11, 13, 14 and megakaryocytes 15, 16 , which are more difficult to obtain using the embryoid body method or other feeder cell lines 17 . Although OP9 coculture was developed initially for differentiation of hESCs 11 , we found that this differentiation system is also very effective for generation of hematopoietic cells from hiPSCs 18 . We demonstrated that all hematopoietic progenitors in hESC differentiation cultures can be identified by the expression of CD43 (ref. 19) 19 . This population of cells can be expanded with granulocyte-macrophage colony-stimulating factor (GM-CSF) and used to generate almost all types of mature myeloid cells using a particular cytokine combination 21 . Recently, we showed that hiPSCs can be differentiated into blood and endothelial cells as well. Although we observed substantial variation in the differentiation efficiency of seven tested hiPSC lines, the pattern of hiPSC differentiation was very similar to that of hESCs 18, 21 . In this paper, we provide the protocol for the generation of hematopoietic progenitors and mature myeloid cells from hESCs and hiPSCs. This protocol is optimized from our earlier reports and is composed of three major steps: (i) induction of hematopoietic differentiation by coculture of hPSCs with OP9 bone marrow stromal cells 11, 22 , (ii) short-term expansion of multipotent myeloid progenitors with a high dose of GM-CSF 21, 23 and (iii) directed differentiation of myeloid progenitors into neutrophils, eosinophils, dendritic cells (DCs), Langerhans cells (LCs), macrophages and osteoclasts 21 . Although other methods for the generation of neutrophils, DCs, monocyte/macrophages and osteoclasts from hESCs have been described [24] [25] [26] [27] [28] [29] , the progenitors that give rise to mature myeloid cells in these differentiation systems remain obscure. Our method for the generation of myelomonocytic cells is based on the generation and expansion of prospectively identifiable lin − CD34 + CD43 + CD45 + multipotent hematopoietic progenitors from hPSCs. Applying this approach when differentiating hPSCs that have been genetically engineered to conditionally express specific genes, or hPSCs obtained from patients with a specific genetic abnormality, will make it possible to analyze the effects of genes and oncogenes on myeloid development, lineage specification and leukemic transformation. In addition, this method can provide an unlimited supply of homogenous populations of myeloid progenitors (Fig. 1) .
Although we use OP9 coculture to generate lin − CD34 + CD43 + CD45 + cells from hPSCs, these multipotent progenitors could be potentially obtained by other methods, such as embryoid body or 2D cultures with cytokines, and used for production of mature myelomonocytic cells. However, it is important to remember that hPSC differentiation is a continuous process in which multipotent progenitors arise within a specific time frame that is highly influenced by differentiation conditions. This time frame should be determined by careful kinetic analysis of hematopoietic differentiation by flow cytometry and CFC assay. For example, in OP9 coculture, almost all CD45 + cells generated at day 8 or 9 of differentiation are lin − CD34 + . However, on days 10-12 of culture, most of the CD45 + cells acquire the expression of CD14 and CD15 myelomonocytic lineage markers. This is indicative of their advanced maturation status and associated with a decrease in multipotential CFC capability 18 . Although slight differences in the kinetics of hematopoiesis between different hESC and hiPSC lines have been reported in the embryoid body system 27 , we found a very similar time frame of hematopoietic development from H1 hESC and hiPSC lines in coculture with OP9 18 . On the basis of these data, we concluded that the kinetics of hematopoietic differentiation depend mostly on differentiation conditions rather than on intrinsic properties of hPSC lines.
Differentiation of myeloid progenitors. By applying different cytokine combinations, lin − CD34 + CD43 + CD45 + cells can be differentiated into almost all types of mature myelomonocytic cells (Fig. 2) . The optimal cytokine combination is GM-CSF, interleukin 4 (IL-4) and tumor necrosis factor-α (TNF-α) for the generation of DCs; GM-CSF, transforming growth factor-β1 (TGF-β1) and TNF-α for LCs; M-CSF and IL-1β for macrophages; G-CSF for neutrophils; and IL-3 and IL-5 for eosinophils. To maximize osteoclast production, we first expand osteoclast progenitors with GM-CSF and Vitamin D3 in poly (2-hydroxyethyl methacrylate) (pHEMA)-coated flasks, and then induce their maturation in cultures supplemented with GM-CSF, Vitamin D3 and nuclear factor κB ligand (RANKL). For efficient differentiation into neutrophils and eosinophils, lin -CD34 + CD43 + CD45 + cells should be cultured on OP9 feeders because granulocytic differentiation in feeder-free conditions is much less effective.
Characterizing differentiated cells. The identity of differentiated cells can be established by the analysis of cell morphology via cytospins and phenotype by flow cytometry 21, 22 (Fig. 2) . The mature neutrophils in differentiation cultures are identified by the expression of neutrophil marker CD66b and intracellular lactoferrin. The hPSC-derived eosinophils lack CD66b and lactoferrin expression but express major basic protein and eosinophilic peroxidase intracellularly. In addition, hPSC-derived eosinophils do not express the CD15, CD16, CD64 and CD123 molecules that are typically detected on neutrophils. Macrophages generated from hPSCs are distinguished from other types of myelomonocytic cells by the CD115 Percoll solution (Sigma-Aldrich, cat. no. P-1644) PBS, powdered, without calcium and magnesium (GIBCO-Invitrogen, cat. no. 21600-044) PBS (10×, GIBCO-Invitrogen, cat. no. 70011-044) Gelatin from porcine skin, Type A (Sigma-Aldrich, cat. no. G-1890) EDTA (0.5 M, pH 8.0; GIBCO-Invitrogen, cat. no. 15575-038) Monothioglycerol (MTG, Sigma-Aldrich, cat. no. M-6145) FBS, defined (HyClone, cat. no. SH30070.03)  crItIcal The FBS used in this protocol is defined FBS. Use FBS directly without the heat inactivation step for OP9 culture, hematopoietic differentiation, expansion of myeloid
progenitors and the generation of mature myelomonocytic cells from hPSCs. Heat inactivation does not benefit culture but usually results in a higher adipogenic effect on OP9  crItIcal We have found that different lots of HyClone-defined FBS provide relatively stable hematopoietic differentiation in hPSC/OP9 coculture and support efficient OP9 growth without substantial adipogenesis. Results from other suppliers are more variable. Trypsin/EDTA (0.05% (wt/vol)/0.5 mM; HyClone, cat. no. SH30236.02) Add 50 mg of collagenase to 50 ml of DMEM/F-12 basal medium and sterilize the solution by filtration using a 0.22-µm membrane filter. Keep the solution at 2-8 °C and use for up to 1 week. Gelatin solution (0.1% (wt/vol)) Add 500 mg of gelatin to 500 ml of endotoxin-free reagent-grade distilled water. Solubilize and sterilize by autoclaving for 20 min at 121 °C. Store the solution at 4 °C for up to 6 months. Keep the medium sterile. Magnetic cells sorting (MACS) buffer MACS buffer contains 5% (vol/vol) FBS and 2 mM EDTA in PBS (Ca 2 + and Mg 2 + free). For 500 ml, add 25 ml of FBS and 2 ml of 0.5 M EDTA (pH 8.0) into Ca 2 + -and Mg 2 + -free PBS. Sterilize MACS buffer by filtration using a 0.22-µm membrane filter and store at 2-8 °C for up to 6 months. Optional: After filtration, close the lid Sterilize the solution by filtration using a 0.22-µm membrane filter and store for up to 6 months at 2-8 °C. Reconstitution of cytokines Reconstitute cytokines according to the product information provided by manufacturer; see Table 3 for details. Vials of cytokine products in lyophilized pellet state should be centrifuged at maximum speed (21,000g) for 1 min with microcentrifuge to precipitate pellets before opening vials. Distilled water and all buffers should be sterilized by filtration with a 0.22-µm membrane filter.  crItIcal Perform the entire procedure in a sterile biosafety cabinet. Read the product information sheet carefully before preparation of working aliquots of all cytokines. Citric acid solution, 10 mM (pH 3.0) Add 1.643 g citric acid anhydrous and 0.426 g sodium citrate dihydrate to 1 liter of water, and then sterilize the solution by filtration using a 0.22-µm membrane filter. Store the solution at room temperature for up to 6 months. Tris buffer, 5 mM (pH 7.6) Add 0.61 g Tris base to 1 liter of distilled water. Adjust pH to 7.6 with hydrochloric acid, and sterilize the solution by filtration using a 0.22-µm membrane filter. Store the solution at room temperature for up to 6 months. Diluted buffer for Wright stain procedure Mix 30 ml of protocol phosphate buffer (pH 6.4) with 100 ml of deionized water. Store at room temperature for up to 6 months. Media composition Prepare stocks of α-MEM basal medium, DMEM, DMEM/F-12 and IMDM freshly from powder according to the manufacturer's instructions; sterilize by filtration using a 0.22-µm membrane filter and store for up to 2 months at 2-8 °C. See below for preparation instructions for specific types of media; blank fields in "final concentration" indicate solvents, and as such they are not expressed as concentrations.
MEF growth medium Prepare 500 ml of MEF growth medium as shown. Sterilize the medium by filtration using a 0.22-µm membrane filter and store for up to 3 weeks at 2-8 °C.
hESC culture medium Prepare 250 ml of hESC culture medium as shown. Sterilize the medium by filtration using a 0.22-µm membrane filter and store for up to 2 weeks at 2-8 °C.
hiPSC culture medium Prepare 250 ml of hiPSC culture medium as shown. Sterilize the medium by filtration using a 0.22-µm membrane filter and store for up to 2 weeks at 2-8 °C.  crItIcal Note that the basic FGF concentration for hiPSC maintenance should be 2.5 times higher than that for hESCs to lessen the effect of variations in MEF quality on culture of hiPSCs.
Mouse OP9 bone marrow stromal cell culture medium Prepare 250 ml of medium as shown. Sterilize the medium by filtration using a 0.22-µm membrane filter and store for up to 2 weeks at 2-8 °C. Differentiation (hPSC/OP9 coculture) medium Prepare 500 ml of medium as shown. Sterilize the medium by filtration using a 0.22-µm membrane filter and store for up to 2 weeks at 2-8 °C. Optional: ascorbic acid solution (50 mg ml -1) can be added to achieve 50 µg ml -1 final concentration.
Multipotent myeloid progenitor expansion medium Prepare medium as shown. Volume of the medium will vary depending on input cell number.
In this protocol, we use 1 ml of medium for ~1 × 10 6 cocultured cells. The complete medium is prepared freshly and GM-CSF is added right before use.
Neutrophil differentiation medium Prepare medium as shown. Volume of the medium will vary depending on input cell number. In this protocol, we use 1 ml of medium for ~2 × 10 4 cells. The complete medium is prepared freshly and all cytokines and supplements are added right before use.
Eosinophil differentiation medium Prepare medium as shown. Volume of the medium will vary depending on input cell number. In this protocol, we use 1 ml of medium for ~2 × 10 4 cells. The complete medium is prepared freshly and all cytokines and supplements are added right before use.
DC differentiation medium
Prepare as shown. Volume of the medium will vary depending on input cell number. In this protocol, we use 1 ml of medium for 10 5 cells. The complete medium is prepared freshly, and all cytokines and supplements are added right before use. LC differentiation medium Prepare as shown. Volume of the medium will vary depending on input cell number. In this protocol, we use 1 ml of medium for 10 5 cells. The complete medium is prepared freshly, and all cytokines and supplements are added right before use.
IMDM medium containing 10% (vol/vol) FBS Prepare medium as shown.
Sterilize the medium by filtration using a 0.22-µm membrane filter and keep sterile for up to 2 weeks at 2-8 °C.
Macrophage differentiation medium Prepare medium as shown. Volume of the medium will vary depending on input cell number. In this protocol, we use 1 ml of medium for 10 5 cells. The complete medium is prepared freshly and all cytokines and supplements are added right before use.
Osteoclast progenitor expansion medium Prepare medium as shown. Volume of the medium will vary depending on input cell number. In this protocol, we use 1 ml of medium for 2 × 10 4 cells. The complete medium is prepared freshly and all cytokines and supplements are added right before use. Osteoclast maturation medium Prepare medium as shown. Volume of the medium will vary depending on input cell number. In this protocol, we use 1 ml of medium for 5 × 10 4 cells. The complete medium is prepared freshly and all cytokines and supplements are added right before use.
IMDM medium containing 20% (vol/vol) FBS Prepare medium as shown.
EQUIPMENT SETUP Gelatin-coated 10-cm culture dish and six-well tissue culture plate Add 7-8 ml of autoclaved gelatin solution to a 10-cm culture dish or 2 ml to each well of a six-well tissue culture plate. Allow the gelatin solution to cover the entire plastic surface and incubate for at least 3 h at 37 °C in an incubator. Dishes and six-well plates containing gelatin solution can be stored for up to several days at 37 °C in a CO 2 incubator. Do not allow the wells to dry. Before use, aspirate the gelatin solution from the dish. pHEMA-coated culture flask Add 5 ml of 10% (wt/vol) pHEMA/ethanol solution to a T75 tissue culture flask or 2 ml of the solution to a T25 tissue culture flask. Rotate the flask gently to allow pHEMA solution to cover the entire surface of the flask. Ensure that the flask is completely covered with pHEMA solution. Tip the flask to remove excess pHEMA solution and save to reuse. After coating, dry the flask overnight in a sterile biosafety cabinet, close the cap and store under sterile conditions at room temperature until needed for use.  crItIcal Treatment with pHEMA should be done quickly to avoid irregular coating as a result of rapid ethanol evaporation. 
2|
Inactivate MEFs with γ-irradiation at 8,000 rad.
3|
Resuspend MEFs at 2 × 10 5 cells per ml in prewarmed (at 37 °C) MEF growth medium.
4| Add 2 ml per well of prewarmed MEF growth medium and then dispense MEF suspension on a gelatin-coated six-well plate (1 ml per well).  crItIcal step Distribute MEFs evenly with a back/forth and right/left movement twice. Irregular distribution of MEFs may cause death and unwanted differentiation of hPSC colonies during culture.
5|
Incubate MEF plates in a CO 2 incubator at 37 °C for at least 24 h before adding hPSCs.  crItIcal step MEFs should be used for hPSC passage within 1 week. Before plating hPSCs (Step 15), aspirate MEF medium, add 2 ml of PBS, swirl once and aspirate PBS. Add 2 ml of prewarmed hPSC medium and place the plate into CO 2 incubator at 37 °C.
hes/ipsc culture • tIMInG 7 d 6| Aspirate hPSC growth medium from one well of the six-well plate of hESCs or iPSCs.  crItIcal step Note that cells will need to be split once every 6-7 d.
7|
Wash cells with 2 ml per well of PBS (Ca 2 + -and Mg 2 + -free); store at room temperature.
8| Add 1 ml per well of collagenase IV solution (1 mg ml -1 ) and incubate at 37 °C in a CO 2 incubator until the edges of the hPSC colonies begin to curl (approximately 7-10 min).
9| Add 1 ml of hESC or hiPSC growth medium and break up the colonies into small cell aggregates by pipetting gently.  crItIcal step After collagenase treatment, hPSC colonies are loosely attached and can be collected by gentle pipetting. Do not use excessive mechanical force or scraping, which can provoke spontaneous differentiation.
10|
Transfer cells to a 15-ml conical tube.
11|
Centrifuge at 200g at room temperature for 3-5 min.
12| Aspirate the medium gently without disturbing the pellet.
13|
Resuspend cells in 3 ml of hESC or hiPSC growth medium, and wash cells by repeating Steps 11 and 12.
14| Resuspend cell pellet in 3 ml of hESC or hiPSC growth medium and break hESC/hiPSC colonies into small aggregates with a glass pipette.
15|
Plate 0.5 ml per well of cell suspension onto the MEF-grown six-well plate from Step 5. ? troublesHootInG 16| Feed hPSCs daily by replacing the old medium with 3 ml of prewarmed hESC or hiPSC medium.
17|
Passage undifferentiated hES/iPSCs (Fig. 1a) weekly at a density of 1.2 × 10 6 to 1.5 × 10 6 cells per well on MEFs.  crItIcal step If spontaneous differentiation of hESCs or hiPSCs occurs, differentiated hPSC colonies should be eliminated during the maintenance; observe hPSCs every day before changing the medium. Mark differentiated colonies with an objective marker under the inverted microscope and aspirate marked areas using a glass Pasteur pipette while feeding hPSC with fresh medium.  crItIcal step Alternatively, hPSCs can be maintained under feeder-free conditions 34 . In OP9 coculture system, we did not observe substantial differences in the efficiency of hematopoietic differentiation of hPSCs maintained on MEFs or in feeder-free cultures. 
21|
Transfer cell suspension into a 15-ml conical tube and centrifuge for 5 min at 300g at room temperature.
22|
Aspirate supernatant and resuspend cells in 1 ml of OP9 growth medium.
23|
Add 100 µl of cell suspension to 10 ml of OP9 growth medium and plate cells onto 10-cm gelatin-coated culture dishes.  crItIcal step It is essential to culture OP9 on gelatin-coated plates to prevent spontaneous adipogenesis. ? troublesHootInG 24| When cultures are confluent, split one dish for maintenance. This should occur after ~4 d of growth.
25|
To prepare overgrown OP9 for coculture with hPSCs, change half of the medium after 4 d of culture on gelatin-coated plates and incubate for an additional 4-8 d to achieve a dense OP9 monolayer.  crItIcal step OP9 should be split every 4 d for maintenance/expansion. OP9 used for hPSC differentiation should be fed with fresh medium at confluence (day 4) and incubated for an additional 4-8 d to form a dense monolayer embedded in extracellular matrix.
Hematopoietic differentiation on op9 • tIMInG 9 d 26| Remove overgrown OP9 dishes prepared for coculture from the CO 2 incubator.
27|
Aspirate OP9 growth medium.
28| Add 10 ml of differentiation medium and keep at 37 °C in a CO 2 incubator.
29| From one well of a six-well hPSC plate from Step 17, aspirate hES/hiPSC growth medium. Add 1 ml of collagenase IV solution (1 mg ml -1 ) and incubate cells for 10 min at 37 °C.
30| Add 1 ml per well of differentiation medium directly to the well and break up colonies into small cell aggregates by gentle pipetting. Transfer cells into a 15-ml conical tube.  crItIcal step hPSCs for differentiation studies should be prepared as small aggregates. Single hPSCs will not survive on OP9.
31| Centrifuge cells at 200g for 3-5 min at room temperature.
32|
Aspirate the medium gently without disturbing the pellet.
33|
Resuspend the cell pellet with 1 ml of differentiation medium.
34| Add 1 ml of hES/hiPSC suspension to one OP9 dish prepared in Steps 26-28.  crItIcal step Efficiency of hematopoietic differentiation is substantially affected by the density of hPSCs plated on OP9. In our experience, the optimal plating density of hPSCs is 1.0 × 10 6 to 1.5 × 10 6 cells per 10-cm dish of OP9. To estimate the number of cells in a suspension consisting of small hPSC aggregates, one well of a six-well plate can be used to prepare a single cell suspension by treatment with trypsin for cell counting. Alternatively, aliquots of hPSC aggregates can be collected, treated with trypsin and counted.
35|
Distribute cells evenly with a back/forth and right/left movement twice.
36|
The following day (day 1), aspirate all of the media to waste and replace with 20 ml of prewarmed differentiation medium.
37|
On day 4, change half of the medium.
38|
On day 6, change half of the medium.
39|
To collect cells on day 9, aspirate the supernatant and add 5 ml of prewarmed collagenase solution (1 mg ml -1 ) to each dish of hPSC/OP9 coculture and incubate for 30 min at 37 °C in a CO 2 incubator.
40|
Remove the collagenase solution and keep it on ice in a 15-ml conical tube for subsequent collection of trypsin-digested cells (cell collection tube).  crItIcal step hPSC/OP9 coculture produces collagen-rich matrix, and pretreatment with collagenase is essential to achieve efficient digestion of cells with trypsin. Because some cultures might form an excessive amount of extracellular matrix, the time of treatment with collagenase can be extended up to 40-50 min to achieve complete dissociation and maximize cell recovery. 44| Centrifuge the cell suspension at 300g for 5 min at room temperature.
45|
Wash cells once by discarding the supernatant and adding 5 ml of MACS buffer to cell pellets, followed by pipetting and centrifugation at 300g for 5 min at room temperature.
46|
Resuspend cells in 1-2 ml of MACS buffer and keep on ice. Cells are ready to be used in further applications such as flow cytometry, CFC assay and further differentiation.  crItIcal step The success of subsequent steps in this differentiation protocol largely depends on effective induction of hematopoietic differentiation and lin − CD34 + CD43 + CD45 + progenitors in coculture with OP9. Therefore, analysis of CD43 expression and simultaneous detection of CD235a/CD41a + and CD45 + cells within the CD43 + population can be performed to confirm myeloid commitment 22 (see Fig. 1 ).  crItIcal step Because we observed a decline in the hematopoietic differentiation capacity of hESCs after passage 50, we do not recommend the use of hESC lines beyond this passage. OP9 cells should not be used beyond passage 60 because of a substantial decrease in hematopoiesis-inductive potential. 
51|
Pellet the cells by centrifugation at 250g for 5 min at room temperature.
52|
Resuspend cells with 5 ml of MACS buffer in a 15-ml tube.
53| Underlay cell suspension with 1.0-1.5 ml of Percoll solution. Place a 1-ml plastic serological pipette filled with Percoll solution into the tube with cell suspension so that the pipette tip touches the bottom of the tube. Very carefully dispense Percoll solution to underlay cell suspension, avoiding mixing.
54|
Centrifuge the tube at 300g for 10-15 min at room temperature.
55|
Aspirate supernatant and interface containing dead cells and debris without disturbing the cell pellet.
56|
Resuspend the cell pellet with 5 ml of MACS buffer and centrifuge at 250g for 5 min at room temperature. Take an aliquot of the resuspended cells before centrifugation to count the number of isolated cells.
57|
Aspirate supernatant and add 0.2 ml of MACS buffer to cell pellet.
58| Add 1 µl of anti-human CD235a-phycoerythrin (PE) and 5 µl of anti-human CD41a-PE antibodies per 10 6 cells.  crItIcal step Usually, cells collected after Percoll separation are free of residual OP9 cells. If substantial contamination of human cells with OP9 cells occurs, 10 µl of anti-mouse CD29-PE antibody can optionally be added to the cell pellet to deplete the mouse cells. The presence of contaminating OP9 cells in suspension can be evaluated by flow cytometry using mouse-specific CD29 antibodies 22 .
59| Set up tube on the MACS mixer and incubate at the lowest rotation speed at 4 °C for 15-20 min.
60|
Wash cells with ice-cold MACS buffer by adding 5 ml of MACS buffer to the cell suspension, followed by pipetting and centrifugation at 300g for 5 min at 4 °C; resuspend in 0.4 ml of MACS buffer and add 10 µl of anti-PE magnetic beads.
61| Repeat
Step 59.
62| Wash cells with ice-cold MACS buffer, as described in
Step 60, and resuspend in 1 ml of MACS buffer.
63|
Filter cells through a 30-µm preseparation filter.  crItIcal step It is important to filter cells before magnetic separation to remove large cell aggregates that may block the magnetic column.
64|
Assemble the MACS-LD separation column according to the manufacturer's instructions.
65|
Wash column with 2 ml of MACS buffer.
66|
Apply the cell suspension from
Step 63 into the LD column, allowing cells to pass completely through the column into a 15-ml collection tube.
67| Wash the column with 2 ml of MACS buffer and collect in the same collection tube.
68|
Recap and remove the collection tube with unlabeled cells (CD235a-CD41a human cells).
69|
Centrifuge cells at 300g for 5 min at 4 °C.
70|
Aspirate supernatant and add 80 µl of MACS buffer and 20 µl of anti-human CD45-fluorescein isothiocyanate (FITC) antibody.
71|
Place the tube on the MACS mixer and incubate at the lowest rotation speed at 4 °C for 15-20 min.
72| Wash cells with ice-cold MACS buffer as described in
Step 60; resuspend in 80 µl of MACS buffer and add 20 µl of anti-FITC magnetic beads.
73| Repeat
Step 69.
74|
Wash cells with ice-cold MACS buffer, as described in
75|
Filter cells through a 30-µm preseparation filter.
76| Assemble MACS-LS separation unit according to the manufacturer's instructions.
77|
Rinse the column with 2 ml of MACS buffer.
78|
To purify CD235a/CD41a -CD45 + multipotent myeloid progenitors, apply the cell suspension from
Step 75 into the LS column, allowing cells to pass completely through the column into the collection tube.
79| Wash the column with 2 ml of MACS buffer and collect in the same collection tube and then discard.
80|
Remove the column from the magnet and place in an empty 15-ml tube.
81| Wash out CD45
+ cells with 5 ml of MACS buffer using the plunger supplied with the column.
82|
83|
Resuspend cells in 0.2 ml of MACS buffer and keep on ice. Cells are ready to be used for further differentiation.
? troublesHootInG Differentiation of hpsc-derived myelomonocytic cells 84| Differentiate hPSC-derived lin -CD34 + CD43 + CD45 + progenitors with option A for neutrophils, option B for eosinophils, option C for macrophages, option D for DCs, option E for LCs and option F for osteoclasts.
(iii) On days 2-3, add 5 ml of complete LC differentiation medium with TNF-α and TGF-β1 (2.5 ng ml − 1  crItIcal step Large adhesive and multinucleated cells are markers for mature osteoclasts. However, immature myeloid cells (small, round and nonadherent cells) keep proliferating because of the presence of GM-CSF, and these proliferating cells interfere with osteoclast maturation. Therefore, you should eliminate nonadherent cells by aspiration during regular medium changes. We found that the addition of M-CSF had no effect on the development of osteoclasts in our differentiation system. Moreover, the addition of M-CSF to osteoclast cultures shifted differentiation hiPSCderived myeloid progenitors toward macrophages. 
87|
During centrifugation, label the glass slide and assemble with Cytofuge filter concentrator unit according to the manufacturer's instructions.
88|
Transfer cell suspension (from Step 86) into the sample chamber of the assembled glass slide-Cytofuge filter concentrator unit.
89| Centrifuge samples at 700 r.p.m. (27g) for 4 min at room temperature.
90| Dry the slide completely at room temperature.
91|
Fix the slide by dipping into absolute methanol for 30-60 s at room temperature.
92|
Wright staining: Cover cytospin area with 300 µl of protocol Wright stain and allow to stain for 3 min at room temperature. Ensure that the stain covers the entire area of cells to ensure uniform staining of cells on cytospin.
93| Add 450 µl of buffer diluted to pH 6.4 to the Wright stain-covered slide.
94|
Mix the stain and buffer together by gently rocking slide for 1 min and incubate the mixture for an additional 4 min at room temperature.
95|
Rinse the slide with deionized water and dry completely in air.
96| Drop 2-3 droplets of Cytoseal 60 mounting medium on the stained cell area and cover with a cover slip.
97|
Observe under a conventional bright-field microscope at ×40 or ×100 magnification.
Steps 47-83: Expansion and isolation of lin -CD34 + CD43 + CD45 + hematopoietic progenitors enriched in myeloid CFCs
Step 
